Zytiga Safety Profile & Adverse Events

Safety Profile Overview

CYP17 inhibitor for metastatic prostate cancer. Must be administered with prednisone. Monitored for mineralocorticoid excess effects.

Generic Name

abiraterone acetate

Brand Names

Zytiga

Therapeutic Class

CYP17 Inhibitor

Manufacturer

Janssen

What Pharma Signal Tracks for Zytiga

Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Zytiga, including serious outcomes, hospitalizations, and deaths.
FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Zytiga products.
Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Zytiga Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Zytiga.

curl "https://api.pharma-signal.com/drug/safety/zytiga" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Try the API API Reference

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Zytiga against other CYP17 Inhibitor drugs, or explore the full manufacturer portfolio for Janssen.

Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
Therapeutic class benchmarking — See how Zytiga ranks within CYP17 Inhibitor on serious event rates.
Company portfolio risk — View all drugs from Janssen with aggregate risk exposure.
AI analyst briefs — Get a natural-language safety assessment combining all data sources.